CE Mark Approval Granted to Kantaro COVID-SeroKlir and COVID-SeroIndex Quantitative Antibody Test Kits - Seite 2
"Confirming past COVID-19 infection with specific numerical values helps patients to take control of their health and provides vital information for the clinician trying to understand the long-term impact of COVID-19 on other health issues such as cardiac, lung and kidney health," said Sara Barrington, Kantaro's chief commercial officer. "Additionally, knowing specific levels of neutralizing antibodies a person has produced is an important part of understanding immunity and supporting long-term public health strategies."
"COVID-SeroKlir and COVID-SeroIndex receiving CE mark approval is an important step in the global commercialization plan for these best-in-class quantitative antibody test kits," said Chuck Kummeth, Bio-Techne's president and chief executive officer. "We are prepared to produce up to 10 million tests per month and ready to support any further rapid expansion."
About Kantaro Biosciences
Kantaro Biosciences ("Kantaro"), a Mount Sinai Health System venture, is dedicated to ensuring that high-quality diagnostic tests for critical health
challenges are accessible. The company provides rigorous, results-driven and reproducible diagnostics to advance the care and well-being of people, communities and society. Kantaro specializes in
the rapid scale-up of groundbreaking diagnostic innovations and the creation of partnerships to bring these crucial technologies to market. For more information,
visit www.kantarobio.com or @KantaroBio.
Lesen Sie auch
About Bio-Techne
Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical
diagnostic communities. Bio-Techne products assist scientific investigations into biological processes and the nature and progress of specific diseases. They aid in drug discovery efforts and
provide the means for accurate clinical tests and diagnoses. With thousands of products in its portfolio, Bio-Techne generated approximately $739 million in net sales
in fiscal 2020 and has over 2,300 employees worldwide. For more information on Bio-Techne and its brands, please visit www.bio-techne.com.